Coya Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 3.98 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 93.36M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The company develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages in Phase 2 trial for use in the treatm...